Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: MK-0646|DRUG: Dasatinib
Sponsor: M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb|Merck Sharp & Dohme LLC|Commonwealth Foundation for Cancer Research